Novo’s Drug Ingredient Could Do More Than Weight Loss:
Initial reading notes that the glucose regulating drug potential of Novo Nordisk’s main ingredient may extend beyond weight loss, pending late-stage results
Global obesity drug expansion: Lilly and Novo eye growth
The focus is on global obesity drug expansion as Lilly and Novo Nordisk broaden production capacity to meet anticipated growth and wider medical coverage
Novo US Market Leadership Strengthened with New US Chief
The leadership change at Novo Nordisk reflects its commitment to securing Novo US market leadership amid increasing competition and pricing pressures in the
Metsera stock decline as Novo withdraws from Pfizer bidding
The Metsera stock decline reflects investor concerns following Novo Nordisk's withdrawal from the bidding process, impacting the company's valuation and market
Bloomberg Deals Today: SoftBank Marvell Pfizer Novo in Focus
SoftBank Marvell Pfizer Novo reflect ongoing strategic moves in the technology and healthcare sectors, with SoftBank exploring semiconductor investments and
Novo Cuts 11% of Workforce and Accelerates Efforts to Compete with Eli Lilly in the Obesity Market
Novo Nordisk announced plans to reduce its workforce by approximately 11%, as part of a broader strategy to accelerate its efforts in the obesity treatment market. The Danish pharmaceutical company…